penicillin g sodium - Profile

What are the generic sources for penicillin g sodium and what is the scope of freedom to operate?

Penicillin g sodium is the generic ingredient in one branded drug marketed by Bristol Myers Squibb, Copanos, Pharmacia And Upjohn, Sandoz, and Watson Labs Inc, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.

Summary for penicillin g sodium

US Patents:	0
Tradenames:	1
Applicants:	5
NDAs:	5

US Patents and Regulatory Information for penicillin g sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers Squibb	PENICILLIN G SODIUM	penicillin g sodium	INJECTABLE;INJECTION	061935-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Copanos	PENICILLIN G SODIUM	penicillin g sodium	INJECTABLE;INJECTION	061051-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Pharmacia And Upjohn	PENICILLIN G SODIUM	penicillin g sodium	INJECTABLE;INJECTION	061046-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Sandoz	PENICILLIN G SODIUM	penicillin g sodium	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS	065068-001	Feb 26, 2001		RX	No	Yes
Watson Labs Inc	PENICILLIN G SODIUM	penicillin g sodium	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS	063014-001	Sep 13, 1988		DISCN	No	No

Last updated: July 11, 2026

PENICILLIN G SODIUM Investment Scenario and Fundamentals Analysis (2026)

Penicillin G sodium is an established, off-patent narrow-spectrum beta-lactam antibiotic. The investment setup is driven by low incremental innovation, high commodity-like procurement dynamics, and recurring procurement and supply-risk cycles for sterile injectable antibiotics. Near-term value capture typically flows to manufacturers with validated sterile capacity, reliable sourcing of penicillin intermediates, and consistent regulatory compliance, not to patent exclusivity. Profit pools are constrained by price competition, tender-based contracting, and substitution within beta-lactam formularies.

---

Is Penicillin G Sodium off-patent, and what does that mean for investment returns?

Yes. Penicillin G sodium is off-patent in the US and most major markets, so returns do not rely on ongoing exclusivity. In practice, investors underwrite operational excellence and supply resilience rather than proprietary IP.

What IP still matters if the drug is off-patent?

Even when the active ingredient is not protected, profitability can still be influenced by:

• Manufacturing process patents (sterile formulation steps, crystallization, drying, impurity control, penicillin salt conversion)
• Formulation and stability patents (rare in this segment, but can exist for specific strengths, reconstitution behaviors, or excipient systems)
• Method-of-use patents (usually not the economic driver for generics in established antibacterial classes)
• Regulatory protection via exclusivity for certain listed products (data exclusivity can apply to new formulations or new dosage forms, but this is uncommon for legacy Penicillin G sodium products)

Where the value is created

• Supply certainty (capacity, batch release performance, low sterile contamination rates)
• Regulatory track record (facility inspections, CMC consistency, rapid compliance remediation)
• Cost position (energy, solvents, purification efficiency, yield, contamination control)
• Distribution and contracting (tender success rates, contract carryover, wholesaler relationships)

---

What is the FDA and Orange Book status of Penicillin G sodium?

Penicillin G sodium is generally marketed as an approved antibiotic with multiple generic and authorized versions; the key commercial reality is competitive availability rather than Orange Book exclusivity. The asset’s FDA footprint is typically spread across many ANDA or previously approved applications, with product-level differences in labeling, packaging, and strengths rather than fundamental innovation.

What to look for in Orange Book listings

For investment diligence, the operating question is whether any listed patents appear tied to particular NDCs for Penicillin G sodium strengths. The economic pattern in legacy injectables is:

• limited or no meaningful remaining patent term for the active ingredient itself
• occasional process/formulation listings on specific label variations

Practical investment implication

If remaining listed patents exist, they usually govern specific product configurations, not the entire active ingredient category. For procurement and contracting, that matters because it can create short windows of reduced competition for specific NDCs, but it rarely changes the long-run market outcome.

(Note: a precise Orange Book mapping requires NDC-level data, which is not provided in the prompt.)

---

How does the commercial market work for Penicillin G sodium in the US and Europe?

Penicillin G sodium trades like an antibiotic commodity with institutional demand and procurement controls.

Demand drivers

• Hospital and public health formularies for susceptible infections and targeted treatment when guideline-concordant
• Ongoing need for narrow-spectrum beta-lactam options in certain clinical pathways
• Stockpiling behavior around shortages and supply disruptions

Customer purchasing patterns

• Competitive tenders at system or group purchasing organization (GPO) levels
• Multi-source procurement to manage shortages
• Contract duration typically shorter than for breakthrough therapies, with price renegotiation risk

Price setting

Price is usually dominated by:

• cost-down competition among multiple suppliers
• procurement platform dynamics
• substitution between injectable penicillins (where clinically acceptable)

Europe pattern

In Europe, tender-based pricing and national reimbursement frameworks similarly pressure margins, while quality and supply continuity matter materially for procurement retention.

---

What revenue exposure does an investment case face for Penicillin G sodium?

Revenue exposure is typically concentrated in:

• Institutional injectable antibiotic volumes
• Country-level regulatory and supply execution
• Batch-to-batch CMC performance, including sterile manufacturing release and sterility assurance

Where downside usually comes from

• Sterile manufacturing disruptions (site-level)
• Contamination or batch rejection events
• Regulatory inspection outcomes affecting product flow
• Competitive price resets driven by new entrants or expanding capacity
• Shortage-driven pricing that reverts when supply normalizes

Upside levers

• Winning and retaining long-term tender positions
• Improving manufacturing yield and reducing impurity burden costs
• Reducing lead times and enabling more reliable hospital ordering
• Capturing share in shortage windows when competitors are constrained

---

What competitive landscape exists for Penicillin G sodium, and who tends to win?

In established injectable antibiotics, competitive advantage is usually operational.

Who typically wins

• Manufacturers with high-quality sterile injectable capability and stable batch release histories
• Companies with low-cost access to penicillin intermediates and strong procurement of raw materials
• Firms that can scale without yield loss
• Suppliers with mature regulatory documentation and fast remediation turnaround

What rarely creates advantage

• New patents on the active ingredient (usually expired)
• Exclusive clinical positioning (clinical guidelines rotate, and tender pricing dominates)

---

How strong is the patent estate for Penicillin G sodium?

Overall weak in aggregate, with any remaining protection usually product- and process-specific. For an investment case, patent strength should be treated as:

• a minor determinant of competitive dynamics
• secondary to manufacturing execution and contracting discipline

Typical residual IP categories

• process control patents (impurity profiles, crystallization parameters, drying conditions)
• specific formulations or presentation formats
• packaging and reconstitution-related stability claims, if present for certain NDCs

Litigation posture in legacy antibiotics

For off-patent generics, litigation may still occur, but it is often:

• less frequent than in specialty biologics or on-patent branded markets
• driven by manufacturing process or specific product presentation differences
• resolved via settlements or non-substantive carve-outs rather than long-term market lock

---

Are Paragraph IV challenges relevant for Penicillin G sodium?

Generally low relevance as a top-line driver. Paragraph IV challenges are typically tied to remaining Orange Book-listed patents. With an off-patent ingredient and a long product history, Paragraph IV activity is usually sporadic and not central to the investment story.

What could make it relevant

• Remaining Orange Book-listed patents on specific NDCs
• A company filing an ANDA with a different manufacturing process targeting a narrow set of listed claims
• Facility-linked litigation risk where a competitor disputes method-of-manufacture scope

---

What does the competitive generic entry risk look like for Penicillin G sodium?

Generic entry risk exists continuously because the active ingredient is mature, and the economic model encourages multiple suppliers.

Where entry is blocked

• sterile manufacturing scale and validated processes
• regulatory and quality hurdles
• raw material supply risks
• economics of sterile packaging and distribution

Implication for investors

The primary question is not “Will generics enter?” but “Can an incumbent defend market share with reliable supply at competitive cost while new entrants scale validated operations?”

---

What manufacturing and CMC barriers matter for Penicillin G sodium?

Sterile injectable antibiotics require:

• validated aseptic processing
• stable crystallization and controlled impurities
• robust batch release testing
• strong contamination controls and compliance readiness

Key CMC risk factors

• Penicillin contamination and degradation control during processing and storage
• Moisture and stability management for the salt form
• Consistency of impurity profiles across scale
• Rapid change control execution for equipment and process parameters

Investment diligence focus

• Sterile manufacturing track record and warning letters history
• Batch failure rate trend and root-cause remediation effectiveness
• Supply chain of key raw inputs
• Capacity utilization and contingency planning

---

When does Penicillin G sodium lose exclusivity?

There is no meaningful exclusivity timeline to underwrite for the active ingredient itself. The investment lens is instead on:

• product-level remaining listed patents for specific NDCs (if any)
• data or regulatory exclusivities tied to particular product presentations
• manufacturing approvals and time required for new entrants to validate processes

---

How does Penicillin G sodium compare with alternative beta-lactam antibiotics for investment attractiveness?

Penicillin G sodium competes clinically with other beta-lactams where substitution is possible and formulary rules allow.

Investment comparison framework

• Market structure: commodity injectable vs specialty-like branded
• Substitution: how easily formularies switch among beta-lactams
• Manufacturing intensity: sterile injectable capacity constraints
• Supply risk: sensitivity to raw material sourcing and aseptic execution
• Pricing power: typically low for mature antibiotics

What usually favors other classes

• A broader patent moat or higher differentiation (e.g., long-acting formulations, specialty dosing, or biologics)
• Less tender-driven pricing
• Higher switching costs

For Penicillin G sodium specifically, investment attractiveness depends on capturing manufacturing economics and tender execution rather than differentiation.

---

What litigation and settlement dynamics affect Penicillin G sodium?

In legacy generics, litigation risk is mostly:

• process patent disputes (if any patents remain listed)
• ANDA-related controversies tied to product-specific claims
• facility-related regulatory disputes that impact supply continuity

Settlement impacts

Settlements in mature antibiotics often:

• delay specific NDC launches on narrow claim sets
• preserve market share temporarily for certain strengths
• do not materially change long-run category pricing once multiple suppliers are established

(No litigation docket details were provided in the prompt, so specifics are not stated.)

---

What regulatory risks affect Penicillin G sodium commercialization?

Key regulatory risks for injectable antibiotics are:

• Facility inspection outcomes
• Aseptic processing compliance
• Batch record integrity and data integrity requirements
• Sterility assurance and endotoxin control
• Labeling updates and adverse event reporting compliance

Operational compliance link to revenue

A single compliance event can trigger:

• product holds
• distribution interruptions
• delayed batch release
• tender losses that may take cycles to regain

---

How to build an investment thesis: fundamentals that matter most

An investment case for Penicillin G sodium should underwrite:

1. Manufacturing reliability in sterile injectable operations
2. Cost position and impurity-control yield performance
3. Contracting strength in hospital procurement systems
4. Supply-chain continuity for penicillin intermediates
5. Portfolio diversification to smooth tender and batch release variability

Key diligence checklist

• CMC: sterility assurance system strength and historical deviation rates
• Regulatory: inspection outcomes and remediation timelines
• Commercial: tender win rate and customer concentration
• Financial: gross margin sensitivity to price resets
• Capacity: ability to scale without yield degradation

---

Key Takeaways

• Penicillin G sodium is an off-patent, commodity-like injectable antibiotic; the investment case depends on operational execution, not remaining drug exclusivity.
• Orange Book-driven economics are usually limited; any protection is likely product- and process-specific.
• Competitive dynamics are tender-led with persistent generic entry pressure; margins are constrained by price competition.
• The core differentiators are sterile manufacturing reliability, CMC consistency, and cost position.
• Revenue upside is typically tied to winning procurement share and maintaining uninterrupted supply during competitor constraints.

---

FAQs

1) What factors drive pricing for Penicillin G sodium in hospital tenders?
Tender pricing is driven by competitive bids, available supplier capacity, and batch release reliability, with margin compression as more suppliers win awards.

2) How does sterile manufacturing failure risk impact Penicillin G sodium supply and revenue?
Batch holds and delayed release can cause immediate tender loss and longer-term customer switching if service levels drop.

3) Are there meaningful formulation upgrades for Penicillin G sodium that investors can underwrite?
Upgrades are usually incremental (presentation/strength handling) rather than transformative; investment theses typically rely on manufacturing improvements and contracting.

4) Does Penicillin G sodium face substitution risk from other beta-lactams?
Yes, substitutability through clinical pathways and formularies can shift volumes between beta-lactams depending on guideline and procurement rules.

5) What is the primary due-diligence focus for a Penicillin G sodium manufacturing asset?
Aseptic and CMC performance metrics, inspection history, impurity control capability, and validated capacity expansion without yield loss.

---

References

(No sources were cited because the prompt did not provide NDC-level FDA/Orange Book data, patent numbers, litigation records, or company-specific filings.)